Aduro Biotech Presents Encouraging Anti-Tumor Response Data From…
Aduro Biotech, Inc. today announced the presentation of updated data from an ongoing Phase 1b clinical trial of its immunotherapy product candidate CRS-207 in combination with pemetrexed and cisplatin as front-line treatment for patients with unresecta…